We will highlight lessons learned about optimal dosing of rapamycin in experimental stroke in an attempt to inform dosing of newer generation mTOR inhibitors such as Rapalink-1, to achieve brain cytoprotection. The gene discussed is MTOR; the disease is stroke disorder.